Trazodone

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

Retrieved on: 
Wednesday, February 21, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Therapy, Addiction, Paroxetine, Anxiety, DMT, Mental health, SP, Imipramine, Artificial intelligence, Tri, Serotonin, BPP, Sleep, MT1, HTR, Aripiprazole, Fenfluramine, MDMA, Trazodone, Human, Mammal, Patient, Hallucination, Melatonin, DSM-IV codes, Plasma, ADHD, Literature, Research, Nefazodone, Mouse, Depression, Pharmaceutical industry

“As a result, Enveric now possesses what we believe to be one of the most diverse portfolios of potential drug molecules for the treatment of key, underserved mental health and neurological disorders.

Key Points: 
  • “As a result, Enveric now possesses what we believe to be one of the most diverse portfolios of potential drug molecules for the treatment of key, underserved mental health and neurological disorders.
  • Enveric SNDRI compounds also demonstrate distinct additional serotonin receptor binding profiles that bear similarities to those of the antidepressant Nefazodone and the anxiolytic Buspirone.
  • Enveric NSRI compounds show strong binding to SERT, as well as to the 5-HT1A receptor, known to be a therapeutically valuable target.
  • For more information about Enveric’s novel preclinical compounds spanning multiple, distinct classes of molecules, please visit: https://www.enveric.com/psybrary .

Using ‘trip killers’ to cut short bad drug trips is potentially dangerous

Retrieved on: 
Wednesday, February 14, 2024
Social media, Anxiety, Opioid overdose, Research, Heroin, LSD, Benzodiazepine, Mirtazapine, A&E, MCPP, Perception, Ketanserin, Naloxone, Trazodone, Vomiting, Hyperthermia, Cannabinoid, Olanzapine, Drug, Plasma protein binding, Psilocybin, MDMA, The Doors of Perception, Depression, Post-traumatic stress disorder, Fear, Diazepam, Alprazolam, Agitation, AMT, Protein, PTSD, Hypoventilation, The Beatles, Brain, Mescaline, Environment, Emergency Medicine Journal, Pharmaceutical industry

As interest in psychedelics has grown, so has interest in ways to end a bad trip.

Key Points: 
  • As interest in psychedelics has grown, so has interest in ways to end a bad trip.
  • Recent research reveals that people are giving potentially dangerous advice on social media on how to stop a trip that is less than pleasurable.
  • One of the earliest descriptions of a psychedelic experience in western literature can be found in Aldous Huxley’s 1953 book The Doors of Perception.
  • Research shows that if someone is in a bad mood or depressed then they are more likely to have a bad trip, as are people who take too high a dose.

Trip killers

  • Few clinical studies have examined trip killers, but one has found that ketanserin – a drug used to treat high blood pressure – reverses the psychedelic effects of LSD.
  • A recent article in the Emergency Medical Journal analysed posts on Reddit about trip killers.
  • Trip killers were discussed most often for LSD (235 posts), magic mushrooms (143 posts) and MDMA (21 posts).

Receptor blocking

  • To kill a trip then, one simply has to give the drug user another drug that blocks (rather than activates) the 5-HT2A receptor.
  • Many prescription drugs can do this and they tend to be antipsychotic drugs.
  • Quetiapine from the list above is one popular example, while another antipsychotic, olanzapine, was mentioned in 14 posts in that study.
  • Similarly, the atypical antidepressants trazodone and mirtazapine also block the 5-HT2A receptor.


Colin Davidson has previously received funding from the National Institute on Drug Abuse (NIH, USA) and the European Community for projects related to stimulant drug abuse and novel psychoactive compounds respectively. He is currently a paid consultant with the Defence Science Technology Laboratory (MOD) working on new psychoactive compounds.

New Research Shows Sleep Reset Is First & Only Digital Sleep Solution Clinically Proven to Increase Total Sleep Time by Over One Hour for Short Sleepers

Retrieved on: 
Tuesday, June 6, 2023
TST, University, Zolpidem, Sagrada Reset, Cognitive behavioral therapy, Eszopiclone, Melatonin, Research, University of Arizona College of Medicine – Tucson, Associate, University of Arizona College of Pharmacy, Dementia, Risk, SAN, Trazodone, Psychiatry, Knowledge, Ageing, Cognitive behavioral therapy for insomnia, Benadryl, Female, Reset, Tutoring, Pharmaceutical industry, Sleep, Insomnia

The University of Arizona's Sleep and Health Research Program led the study which shows Sleep Reset's ability to increase sleep time, addressing a significant concern for many healthcare professionals.

Key Points: 
  • The University of Arizona's Sleep and Health Research Program led the study which shows Sleep Reset's ability to increase sleep time, addressing a significant concern for many healthcare professionals.
  • "Remarkably, data from Sleep Reset reveals that this program has the potential to significantly extend the duration of their sleep.
  • Many popular sleep solutions like Trazadone, Benadryl and Melatonin don't even have the clinical evidence to increase total sleep time much at all.
  • Ambien and Lunesta are known to increase sleep time by around 30 minutes, but that's much less than what we've seen from Sleep Reset.

New Data Show Clinically Meaningful Improvements for Investigational Oral Pharmacologic Treatment AD504 in People With Obstructive Sleep Apnea

Retrieved on: 
Thursday, June 2, 2022
Biotechnology, Pharmaceutical, Health, Trazodone, Stroke, Sleep apnea, LinkedIn, Sleep, Central nervous system, CPAP, Obstructive sleep apnea, Relaxation, Cardiovascular disease, Patient, OSA, Diabetes, Risk, Apnea–hypopnea index, Quality of life, Twitter, Population, HB, AHI, Hypertension, Pharmaceutical industry

AD182 also demonstrated a trend towards reduction in HB relative to placebo but the effects were smaller than what was seen for AD504.

Key Points: 
  • AD182 also demonstrated a trend towards reduction in HB relative to placebo but the effects were smaller than what was seen for AD504.
  • An investigational, oral pharmacologic combination dosed once daily at bedtime, AD504 may be beneficial for OSA patients who also experience sleep disturbance.
  • Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea patients with obstructive sleep apnea could benefit from treatment with a safe and effective oral medication dosed once daily at bedtime.
  • Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.

Apnimed Announces Dosing of First Patient in Phase 2 MARIPOSA Confirmatory Trial of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea (OSA)

Retrieved on: 
Thursday, December 16, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, LinkedIn, Hypertension, PROMIS, Patient-Reported Outcomes Measurement Information System, Sleep, Sleep apnea, Stroke, Population, Volunteering, AHI, Obstructive sleep apnea, Interest, Risk, Sleep disorder, Relaxation, Patient, Cardiovascular disease, Quality of life, Trazodone, NCE, Apnea–hypopnea index, Twitter, HB, CPAP, Diabetes, Central nervous system, Pharmaceutical industry, MARIPOSA, AD109, AD504, Obstructive Sleep Apnea, Apnimed, MARIPOSA, AD109, AD504, OBSTRUCTIVE SLEEP APNEA, APNIMED

MARIPOSA also incorporates a sub-study of AD504, a second investigational oral medication being developed by Apnimed as a potential treatment for OSA.

Key Points: 
  • MARIPOSA also incorporates a sub-study of AD504, a second investigational oral medication being developed by Apnimed as a potential treatment for OSA.
  • With the MARIPOSA study underway, we are one step closer to bringing patients a potential new oral treatment option for OSA.
  • Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea patients with obstructive sleep apnea will potentially benefit from treatment with a safe and effective oral medication.
  • Based in Cambridge, Massachusetts, the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.

Apnimed Achieves Meaningful Results in Proof-of-Concept Crossover Study With Oral Therapeutic Candidates AD504 and AD182 for the Treatment of Obstructive Sleep Apnea

Retrieved on: 
Tuesday, November 16, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Heel, Trazodone, Hypopnea, HB, Sleep, Patient, Obstructive sleep apnea, AHI, Â, OSA, Pharmaceutical industry, AD504, Obstructive Sleep Apnea, Apnimed, AD504, OBSTRUCTIVE SLEEP APNEA, APNIMED

Additionally, the studys secondary endpoint was met with a significant reduction of sleep apnea specific hypoxic burden (HB) following treatment with AD504.

Key Points: 
  • Additionally, the studys secondary endpoint was met with a significant reduction of sleep apnea specific hypoxic burden (HB) following treatment with AD504.
  • Were pleased with the reduction in HB demonstrated by AD504 in this small, proof-of-concept, Phase 2 study, said Larry Miller, M.D., Chief Executive Officer of Apnimed.
  • Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea patients with obstructive sleep apnea will benefit from treatment with a safe and effective oral medication.
  • Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.